Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.44 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3810752 | 1.00 | CNR2 (0.53) | CNR2CNR1ALOX15CHEK1CDK2AP1 | |
| SCHEMBL4080887 | 0.91 | ALOX15 (0.57) | CNR2CNR1ALOX15CHEK1 | |
| SCHEMBL3804151 | 0.91 | ALOX15 (0.57) | CNR2CNR1ALOX15CHEK1 | |
| SCHEMBL4092591 | 0.85 | CNR2 (0.60) | CNR2CNR1ALOX15ADORA1 | |
| SCHEMBL3804561 | 0.85 | CNR2 (0.60) | CNR2CNR1ALOX15ADORA1 | |
| SCHEMBL3746177 | 0.85 | CNR2 (0.51) | CNR2CNR1CHEK1CDK2AP1ADORA1 | |
| SCHEMBL3737197 | 0.84 | CNR2 (0.52) | CNR2 | |
| SCHEMBL4095472 | 0.82 | CNR2 (0.59) | CNR2CNR1ADORA1 | |
| SCHEMBL3808774 | 0.82 | CNR2 (0.59) | CNR2CNR1ADORA1 | |
| SCHEMBL4091079 | 0.81 | CHEK1 (0.54) | CNR2CNR1ALOX15CHEK1CDK2AP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338623-B2 | N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | CNR2 2/4885CNR1 1/4885ALOX15 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.